Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Cover
Cover
Financial Statements
Consolidated Statements of Financial Position
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Changes in Shareholders' Equity
Consolidated Statements of Cash Flows
Notes to Financial Statements
Nature of operations and going concern
Basis of preparation
Material Accounting policies
Critical accounting judgments and estimates
Cash
Prepaid expenses
Contract payments
Intangible assets
Property and equipment
Accounts payable and accrued liabilities
Lease obligation
Share capital and reserves
Related party transactions
Income taxes
Financial instruments and risk management
Capital management
Commitments
Segmented information
Subsequent events
Insider Trading Policies and Procedures
Cybersecurity Risk Management and Strategy Disclosure
Accounting Policies
Material Accounting policies (Policies)
Notes Tables
Basis of preparation (Tables)
Material Accounting policies (Tables)
Cash (Tables)
Prepaid expenses (Tables)
Intangible assets (Tables)
Property and equipment (Tables)
Accounts payable and accrued liabilities (Tables)
Lease obligation (Tables)
Share capital and reserves (Tables)
Related party transactions (Tables)
Income taxes (Tables)
Financial instruments and risk management (Tables)
Commitments (Tables)
Notes Details
Basis of preparation (Details)
Material Accounting policies (Details)
Cash (Details)
Prepaid expenses (Details)
Contract payment (Details)
Intangible assets (Details)
Intangible assets - other details (Details)
Property and equipment (Details)
Accounts payable and accrued liabilities (Details)
Lease obligation - Reconciliation of obligation (Details)
Lease obligation - Future payments (Details)
Share capital and reserves- Authorized and issued (Details)
Share capital and reserves - Issuances (Details)
Share capital and reserves - Diluted weighted average number of shares outstanding (Details)
Share capital and reserves - Changes in warrants (Details)
Share capital and reserves - Warrants Outstanding (Details)
Share capital and reserves - Pre-Funded Warrants (Details)
Share capital and reserves - Finders' and underwriters warrants (Details)
Share capital and reserves - Stock options (Details)
Share capital and reserves - Changes in stock options (Details)
Share capital and reserves - Information on stock options (Details)
Share capital and reserves - Fair value of the warrants issued (Details)
Share capital and reserves - Derivative warrant liability (Details)
Share capital and reserves - Fair value of the derivative warrant liabilities (Details)
Related party transactions (Details)
Related party transactions - Management and directors' key management compensation transactions (Details)
Income taxes (Details)
Income taxes - Significant components of the Company's deferred tax assets (Details)
Income taxes - Schedule of losses expire (Details)
Financial instruments and risk management (Details)
Financial instruments and risk management - Company's risk exposures and their impact on the financial instruments (Details)
Financial instruments and risk management - Contractual maturities of these financial liabilities (Details)
Financial instruments and risk management - Foreign Currency Risk (Details)
Commitments - Employment Agreements (Details)
Commitments - Additional Information (Details)
Commitments (Details)
Segmented information (Details)
Subsequent events (Details)
Commitments (Details)
v3.25.1
Commitments (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Commitments
payments for activities related to its clinical trial
$ 323,000
$ 446,000
X
- References
No definition available.
+ Details
Name:
ifrs-full_CapitalCommitmentsAbstract
Namespace Prefix:
ifrs-full_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- References
No definition available.
+ Details
Name:
xrtx_ActivitiesRelatedToClinicalTrialManufacturing
Namespace Prefix:
xrtx_
Data Type:
xbrli:monetaryItemType
Balance Type:
debit
Period Type:
duration